Abstract: Cytochrome P450 (CYP) 2C9, CYP2C8 and CYP2J2 enzymes, which metabolize arachidonic acid (AA) to epoxyeicosatrienoic acids, have cardioprotective effects including anti-inflammation and vasodilation. We have recently shown that some angiotensin II receptor blockers (ARBs) may inhibit AA metabolism via CYP2C8. Using recombinant CYP2C9, CYP2J2 and human liver microsomes (HLMs), the aim was now to compare the ability of six different clinically used ARBs to inhibit AA metabolism in vitro. The rank order of the ARBs for the 50% inhibitory concentration (IC 50 ) of AA metabolism was losartan <telmisartan <irbesartan <candesartan <olmesartan <valsartan via CYP2C9, and telmisartan <irbesartan <olmesartan <losartan <candesartan and valsartan via CYP2J2. The order for the HLMs was losartan <telmisartan <irbesartan <olmesartan <candesartan <valsartan. Some ARBs having lower concentration of IC 50 indicate that these ARBs might inhibit the AA metabolism in the liver.
Epoxyeicosatrienoic acids (EETs) are generated from arachidonic acid (AA) via CYP enzymes and further metabolized to dihydroxyeicosatrienoic acids (DHETs) via soluble epoxide hydrolase (sEH) [1] . EETs have anti-inflammatory [2] and vasodilating [3] effects and might improve insulin sensitivity [4] . When compared to EETs, DHETs exhibit weaker protective effects. Overall, these results suggest that cardiovascular events such as hypertension and myocardial infarction (MI) might be associated with decreased formation of EETs. As EET analogues and sEH inhibitors help increase the bioavailability of EETs, it has been speculated that such agents might be of benefit when treating hypertension [5] and cardiovascular disease [6] or when trying to improve insulin sensitivity [7] .
The microsomal CYP2C9 has been reported to be almost 16% of total CYP content in the human liver [8] . When AA is metabolized by CYP2C9, this primarily produces 14,15-EET, 11,12-EET and 8,9-EET in a ratio of 2.3:1:0.5 [9] . Other studies have demonstrated the importance of CYP2C9 in drug metabolism including phenytoin [10] , sulphonyl urea antidiabetic drugs [11] and coumarin-derived anticoagulants [12] . The allele frequency of CYP2C9*3, which has a lower metabolic activity, has been reported to be 2% and 7% in Japanese and Caucasian, respectively [13] . Furthermore, the AA metabolism by CYP2C9*3/*3 in recombinant human cytochrome P450 was reported to be approximately one-third of the wildtype [14] .
The CYP2J2 protein is mainly expressed in cardiomyocytes [15] . Its gene expression is approximately 10 times higher than that of CYP2C9 or CYP2C8 in heart [16] . During heart failure, CYP2J2-derived EETs suppress endoplasmic reticulum stress that is induced by the elevation of intracellular Ca 2+ and protect the heart against cardiac failure by maintaining the intracellular Ca 2+ homeostasis [15] .
Danazol is a potent inhibitor of CYP2J2 [17] , which is the key enzyme in the metabolism of AA [1] . As danazol also inhibits CYP2C9 and CYP2C8 [17] , this might decrease EET generation through profound inhibition of AA metabolism by all three CYP enzymes. At present, nine polymorphisms of CYP2J2 (CYP2J2*2 to *10) have been identified [18] . The CYP2J2*2, *3, *4, *6, *7, *8, *9 and *10 alleles code for enzymes with less enzymatic activity in vitro against AA compared with the wild-type CYP2J2*1 [19] [20] [21] , whereas the CYP2J2*5-encoded enzyme has normal AA metabolism [19] . Liu et al. [22] reported that CYP2J2 polymorphisms generated less EETs and there was a 1.3 times increased risk of MI in carriers of the CYP2J2*7 variant compared to the wild-type. This is suggestive of CYP2J2 being one of the key enzymes with relevance for the protecting effect against cardiovascular disease [23] .
Angiotensin II receptor blockers (ARBs) are one of first-line drugs used to treat hypertension, particularly in patients with combined risk factors for cardiovascular disease such as diabetes and dyslipidaemia [24] . Although a few previous studies have suggested that ARBs can reduce the risk of coronary Author for correspondence: Takaki Toda, Division of Clinical Pharmacology, Hokkaido Pharmaceutical University School of Pharmacy, 15-4-1, Maeda 7-jo, Teine-ku, Sapporo, Hokkaido 006-8590, Japan (fax +81-11-676-8666, e-mail toda@hokuyakudai.ac.jp).
events [24, 25] , other recent clinical meta-analyses have demonstrated only negligible benefits of some ARBs during a major cardiovascular event such as MI [26] [27] [28] . Other studies have reported that losartan and irbesartan inhibit CYP enzymes [29, 30] , while telmisartan has been shown to be a potent and selective CYP2J2 inhibitor [31] . In a previous study, we demonstrated that ARBs decrease the production of EETs by inhibiting CYP2C8 [32] . It has been demonstrated that losartan and telmisartan accumulate in the liver of rat [33] and human beings [34] , with accumulated concentrations estimated to be higher than the calculated IC 50 s for AA metabolism. Thus, such accumulations could lead to a decrease in the formation of eicosanoids and increase the risk of cardiovascular events.
The aim of this study was to determine and compare the effect of six different ARBs (candesartan, irbesartan, losartan, olmesartan, telmisartan and valsartan) on AA metabolism catalysed by CYP2C9, CYP2J2 and human liver microsomes (HLMs).
Materials and Methods
Chemicals. Losartan potassium and telmisartan were purchased from Sigma-Aldrich (St. Louis, MO, USA), while all other ARBs were purchased from AstaTech (Bristol, PA, USA). 14,15-, 11,12-, 8,9-and 5,6-EET and 14,15-, 11,12-, 8,9-and 5,6-DHET, along with corresponding deuterium-labelled materials (EETs-d 11 and DHETs-d 11 ) used as the internal standard (IS) substances were purchased from Cayman Chemical (Ann Arbor, MI, USA) except for 5,6-DHET-d 11 , which was commercially unavailable. Recombinant CYP2C9 (rCYP2C9), CYP2J2 (rCYP2J2), control microsomes, 150-donor pooled HLMs and NADPH regeneration systems (solutions A and B) were purchased from Becton Dickinson (Franklin Lakes, NJ, USA). Organic solvents were of HPLC grade and purchased from Kanto Chemical Co. Inc. (Tokyo, Japan). The study used OASISâ HLB solid-phase extraction columns, which were purchased from Waters (Milford, MA, USA).
Stock solutions of ARBs were dissolved in methanol (1 mM) and stored at À20°C. The standard stock solutions were prepared by dissolving the EETs and DHETs in ethanol to achieve a concentration of 1 mM, with the exception of 14,15-EET which was 2 mM. Deuterium-labelled EETs, and DHETs were used as the IS solutions and mixed at concentrations of 0.8 mM, with the exception of 8,9-DHETd 11 for which the concentration was 0.4 mM. The standard and IS solutions as well as the solutions that contained the rCYP2C9, rCYP2J2, control microsomes and HLMs were stored at À80°C. NADPH regeneration system solutions were stored at À20°C.
Determination of K m and V max . All incubations were performed in a total volume of 200 lL, with each containing 50 mM phosphate buffer (pH 7.4), rCYP2C9 or rCYP2J2 (10 lL containing 1 nmol P450/mL), and AA (10, 25, 50 and 80 lM for rCYP2C9; 10, 25, 50, 80 and 120 lM for rCYP2J2, respectively). The final ethanol concentration was set within 1% of the incubation medium to avoid any effects on the enzyme activity. After pre-incubation for 3 min. at 37°C, reactions were started by adding a mixture of the NADPH regeneration solutions A and B (12 lL). Reactions were conducted for 30 min. and stopped by ice-cold acetonitrile. The mixture was spiked with 50 lL of IS solution (final concentrations: 8,9-DHET-d 11 , 0.1 lM; other EETs-d 11 and DHETs-d 11 , 0.2 lM) and then diluted with 700 lL water.
Mixtures were mounted on 30 mg OASISâ HLB after the columns had been conditioned using 2 mL of methanol and 2 mL water. Eluates were collected using 2 mL of ethyl acetate, evaporated in vacuo and then resuspended in 50 lL of 50% acetonitrile. Eicosanoids were determined by LC-MS/MS as described in detail by Mukai et al. [35] . All incubations were within the linear range of the AA metabolism with respect to the incubation duration and P450 content.
Incubation study for rCYP. Incubation was performed using the method of Mukai et al. [35] with some modifications. Each ARB stock solution was evaporated and reconstructed to create the final concentration (0, 10, 50, 100 and 500 lM) in the incubation medium. The medium contained 176 lL Tris-HCl buffer (50 mM, pH 7.4), 10 lL solution A and 2 lL solution B of the NADPH regeneration system, and 10 lL rCYP2C9 (2000 pmol P450/mL) or rCYP2J2 (1000 pmol P450/mL) or control microsomes (0.5 mg protein/mL). After pre-incubation of the resultant medium for 3 min. at 37°C, the incubation experiment was started by adding 2 lL of 2 mM AA (final concentration: 20 lM). After incubation for 30 min. at 37°C, the reaction was stopped by adding 50 lL of ice-cold acetonitrile.
Incubation study for HLMs. Angiotensin II receptor blockers stock solution was prepared by following the same steps performed in the rCYP study. The medium contained 212.5 lL Tris-HCl buffer (50 mM, containing EDTA, pH 7.4) and 25 lL HLMs (10 mg protein/mL). After pre-incubation of the resultant medium for 3 min. at 37°C, the incubation experiment was started by adding 12.5 lL of 16 lg/lL NADPH (final concentration: 1 mM). After incubation for 10 min. at 37°C, the reaction was stopped by adding 1 mL of ice-cold ethanol.
Solid-phase extraction. Solid-phase extraction was performed as described in the 'Determination of K m and V max ' section.
Quantitation equipment and condition. An Agilent 1200 series (Santa Clara, CA, USA) LC system consisting of an autosampler, binary pump and column oven was used to separate the samples. Separations were performed on an Ascentis Express C18 column measuring 100 9 2.1 mm, particle size 2.7 lM (Sigma-Aldrich). The mobile phase consisted of 0.1% formic acid in water (A) and 0.1% formic acid in acetonitrile (B). The linear gradient elution performed at a flow rate of 0.3 mL/min. was as follows: 50% B for 27 min., 50-90% B from 27 to 28 min., hold 90% B from 28 to 35 min. and then an 8-min. re-equilibration at 50% B from 35 to 43 min. The typical injection volume was 40 lL. The HPLC system was coupled to an API3200 Q Trap System (Sciex, Framingham, MA, USA) equipped with a turbo ion spray source. Electrospray ionization was performed in the negative ion mode with the optimum values for the nebulizing, turbo spray and curtain gas set at 60, 70 and 10 psi, respectively. The turbo gas temperature was set at 700°C, and the ESI needle voltage was set at À4500 V. Multiple reaction monitoring was employed using nitrogen as the collision gas with a dwell time of 232 msec and 117 msec for EETs and DHETs at each transition, respectively. Data were acquired and processed using Analyst TM (ver.1.4.2; Sciex). Linear calibration curves with 1/y 2 weighting were calculated by analyte/IS peak area ratios and analyte concentrations. The quantitative reproducibility expressed as the interday coefficient of variation was within 10.0% for all values except those for 14,15-EET (13.2%) and 5,6-DHET (21.2%). For the mass to charge ratio (m/z) of the EETs and DHETs, please refer to the method of Mukai et al. [35] .
Data analysis. The production of eicosanoids was assessed as the sum of the EET and DHET concentrations. The production rate was assessed by Dunnett's test. SigmaPlot ver. 12.5 software (Systat Software Inc., San Jose, CA, USA) was utilized for further statistical evaluations and calculations of the K m and 50% inhibitory concentration (IC 50 ). All statistical results were considered significant at p < 0.05.
The R value, which indicates the ratio of the AUC values generated with and without an inhibitor [36] , was calculated by the following equation:
where [I] represents the maximum concentration with the maximum clinical dosage of inhibitors [37] . Incubation studies were conducted based on the assumption that the substrate concentration was almost identical to its K m for each CYP source. The K m values for AA via rCYP2C9 and rCYP2J2 were 12.2 and 24.1 lM, respectively (figs 1 and 2). However, it was not possible to calculate the K m in the HLMs because HLMs includes AA in themselves. R values for the ARBs were calculated using the half value of the IC 50 , with the exception of the CYP2J2 inhibition by telmisartan. As telmisartan has been reported to be a mixed inhibitor of CYP2J2 [31] , we calculated the R value using the IC 50 . Cut-off values of 1.1 were applied to avoid false negatives [37] .
Results

Determination of K m and V max .
The kinetic parameters used to generate eicosanoids as the sum of the EETs and DHETs from AA were determined to be as follows: K m = 12.2 lM, V max = 1.7 pmol/pmol P450/min. for rCYP2C9 (fig. 1) ; and K m = 24.1 lM; V max = 0.38 pmol/ pmol P450/min. for rCYP2J2 ( fig. 2) , respectively.
Angiotensin II receptor blockers inhibited the production of total eicosanoids by rCYP2C9, rCYP2J2 and HLMs in a concentration-dependent manner (figs [3] [4] [5] . Almost all of the 5,6-EET and DHET concentrations were under the detectable range in this incubation study.
Incubation study for rCYPs and HLMs. For the rCYP2C9 incubation study, each of the ARBs significantly but differently inhibited the production of each eicosanoid ( fig. 3 ). The losartan, telmisartan, irbesartan candesartan, olmesartan and valsartan IC 50 values calculated for the AA metabolism with rCYP2C9 were 26.9, 34.6, 84.7, 98.2, 134.5 and over 500 lM, respectively (table 1). The R values for irbesartan, losartan and telmisartan were calculated to be 1.2, which exceeded the 1.1 cut-off value. As the IC 50 value was over 500 lM for valsartan, the R value could not be calculated.
For the rCYP2J2 incubation study, each of the ARBs also significantly but differently inhibited the production of eicosanoids ( fig. 4) . Table 1 shows the IC 50 values for the inhibition of the eicosanoid production in the presence of ARBs. The IC 50 for telmisartan was the lowest (3.99 lM) among all of the tested ARBs. The calculated R values for telmisartan, irbesartan, losartan and olmesartan were 1.4, 1.2, 1.0 and 1.0, respectively, with the R values for telmisartan and irbesartan exceeding the 1.1 cut-off value. As the IC 50 values were over 500 lM for candesartan and valsartan, the R values could not be calculated.
For the HLMs incubation study, candesartan ( fig. 5A ) significantly inhibited the production of the 14,15-and the 11,12-forms at 500 lM (p < 0.01). Irbesartan, olmesartan and losartan ( fig. 5B ,D,C) significantly inhibited production of the 11,12-form at 10 lM (p < 0.01, p < 0.01 and p < 0.05, respectively) and the 14,15-form at 50 lM (p < 0.01). Telmisartan ( fig. 5E ) significantly inhibited production of the 14,15-and 11,12-forms at 10 lM (p < 0.01 and p < 0.05, respectively). Valsartan ( fig. 5F ) had a negligible effect on the production of eicosanoids. 
Discussion
Incubation studies with rCYP2C9 revealed enzyme kinetic parameters for AA metabolism of K m = 12.2 lM and V max = 1.7 pmol/pmol P450/min. (fig. 1) . We have calculated the enzyme kinetic parameters for AA metabolism via CYP2C8 of K m = 17.4 lM and V max = 1.8 pmol/pmol P450/ min. using unpublished data, which will appear elsewhere. Achour et al. reported that mean enzyme abundance of CYP2C9 and CYP2C8 are 16% and 6%, respectively, in livers from adult Caucasians [8] . The CLint (=V max /K m ) of AA by CYP2C8 (0.10 lL/pmol P450/min.) was slightly smaller than that by CYP2C9 (0.14 lL/pmol P450/min.), indicating that both CYP2C9 and CYP2C8 play important roles for AA metabolism in the liver.
As the R values of irbesartan, losartan and telmisartan were higher than the cut-off value, this indicates the possible inhibition of AA and drug metabolism via CYP2C9.
Among all of the tested ARBs, telmisartan was the most potent CYP2J2 inhibitor (table 1) . This finding is consistent with a previously published study that showed telmisartan was a significant and selective inhibitor of CYP2J2 [38] . While we calculated the IC 50 to be 3.99 lM in the current study, Ren et al. [31] reported the IC 50 of telmisartan was 0.42 lM. This difference might possibly be due to the use of different substances to determine the IC 50 values of telmisartan with rCYP2J2 study. Losartan and telmisartan have been reported to accumulate in the liver, with liver concentrations that are approximately 30-40 times higher than those found in plasma, respectively [33, 34] . The maximum plasma concentrations of losartan (100 mg) and telmisartan (80 mg) after a single oral clinical dose have been reported to be 1.74 lM [39] and 1.76 lM [40] , while the liver concentrations were estimated to be about 50 and 30 lM, respectively. However, as their reported liver concentrations were over the IC 50 that we calculated in our current study (table 2), this indicates that these ARBs might inhibit the AA metabolism in the liver. As there is almost a negligible accumulation of irbesartan, olmesartan and candesartan in the liver [41] [42] [43] , these ARBs are thought not to inhibit the production of eicosanoids. However, the accumulation of valsartan in the liver is approximately 7-to 10-fold higher than that found in the plasma [44] . Moreover, the valsartan plasma concentration reported after a clinical dose (160 mg) was 8.72 lM [45] , which is lower than the IC 50 that we calculated in this study (table 1) . Thus, our results suggest that with the exception of losartan and telmisartan, all of the examined ARBs do not inhibit the generation of eicosanoids via the CYP enzymes within the clinical dose range.
In conclusion, ARBs exhibited different degrees of inhibition of the metabolism of AA by CYP2C9, CYP2J2 and HLMs. Results also showed that the R values of irbesartan, losartan and telmisartan for CYP2C9 and irbesartan and telmisartan for CYP2J2 inhibition were higher than the 1.1 cut-off value. The clinical relevance of these findings remains unclear at this stage. In vivo studies should help to understand the possible impact of ARBs on the production of eicosanoids via CYP2C9 or CYP2J2. This might be especially relevant for losartan and telmisartan, considering their known ability to accumulate in the liver that could result in concentrations over the IC 50 .
Additional clinical studies are required to determine the association between CYP polymorphisms and the concentration of eicosanoids, and also the effects of different ARBs in relation to adverse cardiovascular events.
